Despite its potential, targeting the autophagy-lysosome pathway in cancer therapy faces several challenges. The pathway's dual role complicates the development of treatments, as inhibiting autophagy could potentially promote cancer progression in certain contexts. Additionally, cancer cells can exhibit redundancy in survival pathways, potentially bypassing autophagy inhibition. Furthermore, the heterogeneity of tumors means that autophagy may play different roles even within the same tumor type, necessitating personalized approaches to therapy.
